PHARMADRUG INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 CAD | -.--% |
|
-.--% | -45.45% |
| May. 15 | PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine | MT |
| May. 02 | PharmaDrug Announces Directorate Changes | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 4.81M 6.55M |
|---|---|---|---|---|---|
| Net income 2022 | -8M -10.9M | Net income 2023 | -13M -17.71M | EV / Sales 2022 | - |
| Net Debt 2022 | 1.09M 1.49M | Net Debt 2023 | 1.34M 1.83M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.59
x | P/E ratio 2023 |
-0.24
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 month | +20.00% | ||
| 3 months | -50.00% | ||
| 6 months | -25.00% | ||
| Current year | -45.45% |
1 week
0.03
0.04
1 month
0.030.05
Current year
0.020.08
1 year
0.020.08
3 years
0.020.60
5 years
0.021.44
10 years
0.024.55
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Steen
CEO | Chief Executive Officer | - | 23-09-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 80 | 16-12-19 |
David Kideckel
CHM | Chairman | - | 21-08-29 |
Robert Steen
CEO | Chief Executive Officer | - | 23-09-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.03 | -.--% | 96,500 |
| 24-05-29 | 0.03 | -.--% | 25,000 |
| 24-05-28 | 0.03 | -14.29% | 283,695 |
| 24-05-27 | 0.035 | +16.67% | 7,242 |
| 24-05-24 | 0.03 | -25.00% | 237,000 |
Delayed Quote Canadian Securities Exchange, May 31, 2024 at 10:47 am EDT
More quotes
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Companyâs subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -45.45% | 2.35M | |
| +23.03% | 74.04B | |
| -1.52% | 24.18B | |
| +3.67% | 8.46B | |
| +8.55% | 8.34B | |
| -23.71% | 7.64B | |
| +15.20% | 5.33B | |
| +2.68% | 4.12B | |
| -6.90% | 3.92B | |
| +5.56% | 3.89B |
- Stock Market
- Equities
- PHRX Stock
